Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2014 1
2016 2
2017 3
2018 2
2019 7
2020 4
2021 3
2022 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine.
Gugerell A, Sorgenfrey D, Laggner M, Raimann J, Peterbauer A, Bormann D, Suessner S, Gabriel C, Moser B, Ostler T, Mildner M, Ankersmit HJ. Gugerell A, et al. Blood Transfus. 2020 Jan;18(1):30-39. doi: 10.2450/2019.0249-18. Epub 2019 Feb 21. Blood Transfus. 2020. PMID: 30865581 Free PMC article.
DISCUSSION: Three manufacturing steps of APOSEC(TM) were evaluated under Good Laboratory Practice conditions for their efficacy at reducing and inactivating potentially present viruses. It could be demonstrated that all three steps contribute to the viral safety of APOS …
DISCUSSION: Three manufacturing steps of APOSEC(TM) were evaluated under Good Laboratory Practice conditions for their efficacy at re …
Different pro-angiogenic potential of γ-irradiated PBMC-derived secretome and its subfractions.
Wagner T, Traxler D, Simader E, Beer L, Narzt MS, Gruber F, Madlener S, Laggner M, Erb M, Vorstandlechner V, Gugerell A, Radtke C, Gnecchi M, Peterbauer A, Gschwandtner M, Tschachler E, Keibl C, Slezak P, Ankersmit HJ, Mildner M. Wagner T, et al. Sci Rep. 2018 Dec 20;8(1):18016. doi: 10.1038/s41598-018-36928-6. Sci Rep. 2018. PMID: 30573762 Free PMC article.
Therefore, we sought to dissect the molecular composition of EVs present in the secretome and compared wound healing-related activities of these EVs to other subfractions of the secretome and the fully supplemented secretome (MNC(aposec)). Compared to EVs derived from non- …
Therefore, we sought to dissect the molecular composition of EVs present in the secretome and compared wound healing-related activities of t …
Safety and clinical efficacy of the secretome of stressed peripheral blood mononuclear cells in patients with diabetic foot ulcer-study protocol of the randomized, placebo-controlled, double-blind, multicenter, international phase II clinical trial MARSYAS II.
Gugerell A, Gouya-Lechner G, Hofbauer H, Laggner M, Trautinger F, Almer G, Peterbauer-Scherb A, Seibold M, Hoetzenecker W, Dreschl C, Mildner M, Ankersmit HJ. Gugerell A, et al. Trials. 2021 Jan 6;22(1):10. doi: 10.1186/s13063-020-04948-1. Trials. 2021. PMID: 33407796 Free PMC article.
To this end, the cell-free secretome of peripheral blood mononuclear cells (APOSEC) blended with a hydrogel will be applied topically three times weekly for 4 weeks. ...CONCLUSION: We consider our study protocol to be suitable to test topically administered APOSEC i …
To this end, the cell-free secretome of peripheral blood mononuclear cells (APOSEC) blended with a hydrogel will be applied topically …
Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation.
Hoetzenecker K, Assinger A, Lichtenauer M, Mildner M, Schweiger T, Starlinger P, Jakab A, Berényi E, Pavo N, Zimmermann M, Gabriel C, Plass C, Gyöngyösi M, Volf I, Ankersmit HJ. Hoetzenecker K, et al. Basic Res Cardiol. 2012 Sep;107(5):292. doi: 10.1007/s00395-012-0292-2. Epub 2012 Aug 17. Basic Res Cardiol. 2012. PMID: 22899170 Free PMC article.
In addition, APOSEC evidenced a significant vasodilatory capacity on coronary arteries via p-eNOS and iNOS activation. Our data give first evidence that APOSEC reduces the extent of MVO during AMI, and suggest that modulation of platelet activation and vasodilation …
In addition, APOSEC evidenced a significant vasodilatory capacity on coronary arteries via p-eNOS and iNOS activation. Our data give …
Quantitative Hybrid Cardiac [18F]FDG-PET-MRI Images for Assessment of Cardiac Repair by Preconditioned Cardiosphere-Derived Cells.
Winkler J, Lukovic D, Mester-Tonczar J, Zlabinger K, Gugerell A, Pavo N, Jakab A, Szankai Z, Traxler D, Müller C, Spannbauer A, Riesenhuber M, Hašimbegović E, Dawkins J, Zimmermann M, Ankersmit HJ, Marbán E, Gyöngyösi M. Winkler J, et al. Mol Ther Methods Clin Dev. 2020 Jun 15;18:354-366. doi: 10.1016/j.omtm.2020.06.008. eCollection 2020 Sep 11. Mol Ther Methods Clin Dev. 2020. PMID: 32671138 Free PMC article.
We enhanced the effect of CDCs with APOSEC preconditioning (apoCDC) and investigated the reparative effect in a translational pig model of reperfused MI. Supernatants of CDCs, assessed by proteomic analysis, revealed reduced production of extracellular matrix proteins afte …
We enhanced the effect of CDCs with APOSEC preconditioning (apoCDC) and investigated the reparative effect in a translational pig mod …
Long-acting beneficial effect of percutaneously intramyocardially delivered secretome of apoptotic peripheral blood cells on porcine chronic ischemic left ventricular dysfunction.
Pavo N, Zimmermann M, Pils D, Mildner M, Petrási Z, Petneházy Ö, Fuzik J, Jakab A, Gabriel C, Sipos W, Maurer G, Gyöngyösi M, Ankersmit HJ. Pavo N, et al. Biomaterials. 2014 Apr;35(11):3541-50. doi: 10.1016/j.biomaterials.2013.12.071. Epub 2014 Jan 16. Biomaterials. 2014. PMID: 24439416 Free article.
At day 30, animals were randomized to receive porcine APOSEC (n = 8) or medium solution (control; n = 8) injected intramyocardially into the MI border zone using 3D NOGA guidance. ...A trend towards higher LV ejection fraction was observed in APOSEC vs. controls (45 …
At day 30, animals were randomized to receive porcine APOSEC (n = 8) or medium solution (control; n = 8) injected intramyocardially i …
Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myocardial infarction: a preclinical study.
Lichtenauer M, Mildner M, Hoetzenecker K, Zimmermann M, Podesser BK, Sipos W, Berényi E, Dworschak M, Tschachler E, Gyöngyösi M, Ankersmit HJ. Lichtenauer M, et al. Basic Res Cardiol. 2011 Nov;106(6):1283-97. doi: 10.1007/s00395-011-0224-6. Epub 2011 Sep 28. Basic Res Cardiol. 2011. PMID: 21952733 Free PMC article.
Analysis of soluble factors present in APOSEC was performed by enzyme-linked immunosorbent assay (ELISA) and activation of signalling cascades in human cardiomyocytes by APOSEC in vitro was studied by immunoblot analysis. Intravenous administration of a single dose …
Analysis of soluble factors present in APOSEC was performed by enzyme-linked immunosorbent assay (ELISA) and activation of signalling …
Therapeutic potential of lipids obtained from γ-irradiated PBMCs in dendritic cell-mediated skin inflammation.
Laggner M, Copic D, Nemec L, Vorstandlechner V, Gugerell A, Gruber F, Peterbauer A, Ankersmit HJ, Mildner M. Laggner M, et al. EBioMedicine. 2020 May;55:102774. doi: 10.1016/j.ebiom.2020.102774. Epub 2020 May 8. EBioMedicine. 2020. PMID: 32403085 Free PMC article.
FUNDING: This research project was supported by the Austrian Research Promotion Agency (Vienna, Austria; grant "APOSEC" 862068; 2015-2019) and the Vienna Business Agency (Vienna, Austria; grant "APOSEC to clinic" 2343727)....
FUNDING: This research project was supported by the Austrian Research Promotion Agency (Vienna, Austria; grant "APOSEC" 862068; 2015- …
Safety and tolerability of topically administered autologous, apoptotic PBMC secretome (APOSEC) in dermal wounds: a randomized Phase 1 trial (MARSYAS I ).
Simader E, Traxler D, Kasiri MM, Hofbauer H, Wolzt M, Glogner C, Storka A, Mildner M, Gouya G, Geusau A, Fuchs C, Eder C, Graf A, Schaden M, Golabi B, Aretin MB, Suessner S, Gabriel C, Klepetko W, Tschachler E, Ankersmit HJ. Simader E, et al. Sci Rep. 2017 Jul 24;7(1):6216. doi: 10.1038/s41598-017-06223-x. Sci Rep. 2017. PMID: 28740204 Free PMC article. Clinical Trial.
The primary outcome was the tolerability of the topical application of APOSEC. All adverse events were recorded until 17 days after the biopsy. Local tolerability assessment was measured on a 4-point scale. ...No therapy-related serious adverse events occurred in any of th …
The primary outcome was the tolerability of the topical application of APOSEC. All adverse events were recorded until 17 days after t …
Toxicological testing of allogeneic secretome derived from peripheral mononuclear cells (APOSEC): a novel cell-free therapeutic agent in skin disease.
Wuschko S, Gugerell A, Chabicovsky M, Hofbauer H, Laggner M, Erb M, Ostler T, Peterbauer A, Suessner S, Demyanets S, Leuschner J, Moser B, Mildner M, Ankersmit HJ. Wuschko S, et al. Sci Rep. 2019 Apr 3;9(1):5598. doi: 10.1038/s41598-019-42057-5. Sci Rep. 2019. PMID: 30944367 Free PMC article.
A secretome of stressed peripheral blood mononuclear cells (APOSEC) was successfully tested in a toxicology program, supporting clinical use of the new drug candidate. ...The non-clinical data support the safe topical use of APOSEC in skin diseases related to defici …
A secretome of stressed peripheral blood mononuclear cells (APOSEC) was successfully tested in a toxicology program, supporting clini …
25 results